Antimalarial asexual stage-specific and gametocytocidal activities of HIV protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1334-1337

  Peatey, Christopher L ^a,b   Andrews, Katherine T ^a,c   Eickel, Nina ^d   MacDonald, Timothy ^a   Butterworth, Alice S ^a   Trenholme, Katharine R ^a,b,c   Gardiner, Donald L ^a,b,c   McCarthy, James S ^a,b   Skinner Adams, Tina S ^a,b,c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIMALARIAL AGENT; CHLOROQUINE; DARUNAVIR; DIPHOSPHATE SALT; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; GAMETOGENESIS; GROWTH INHIBITION; IN VITRO STUDY; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANIMALS; ANTIMALARIALS; ERYTHROCYTES; HIV PROTEASE INHIBITORS; HUMANS; LIFE CYCLE STAGES; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PYRIDINES; PYRONES; SULFONAMIDES;

EID: 77149124863     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01512-09     Document Type: Article

References (20)

1. Andrews, K. T., D. P. Fairlie, P. K. Madala, J. Ray, D. M. Wyatt, P. M. Hilton, L. A. Melville, L. Beattie, D. L. Gardiner, R. C. Reid, M. J. Stoermer, T. Skinner-Adams, C. Berry, and J. S. McCarthy. 2006. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob. Agents Chemother. 50:639-648.
2. Briolant, S., P. Parola, T. Fusai, M. Madamet-Torrentino, E. Baret, J. Mosnier, J. P. Delmont, D. Parzy, P. Minodier, C. Rogier, and B. Pradines. 2007. Influence of oxygen on asexual blood cycle and susceptibility of Plasmodium falciparum to chloroquine: requirement of a standardized in vitro assay. Malar. J. 6:44.
3. Dixon, M. W., C. L. Peatey, D. L. Gardiner, and K. R. Trenholme. 2009. A green fluorescent protein-based assay for determining gametocyte production in Plasmodium falciparum. Mol. Biochem. Parasitol. 163:123-126.
4. Grimwade, K., N. French, D. D. Mbatha, D. D. Zungu, M. Dedicoat, and C. F. Gilks. 2004. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 18:547-554.
5. Hughes, A., T. Barber, and M. Nelson. 2008. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J. Infect. 57:1-10.
6. King, J. R., and E. P. Acosta. 2006. Tipranavir: a novel nonpeptidic protease inhibitor of HIV. Clin. Pharmacokinet. 45:665-682.
7. Korenromp, E. L., B. G. Williams, S. J. de Vlas, E. Gouws, C. F. Gilks, P. D. Ghys, and B. L. Nahlen. 2005. Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. Emerg. Infect. Dis. 11:1410-1419.
8. Lambros, C., and J. P. Vanderberg. 1979. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65:418-420.
9. Larder, B. A., K. Hertogs, S. Bloor, C. H. van den Eynde, W. DeCian, Y. Wang, W. W. Freimuth, and G. Tarpley. 2000. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 14:1943-1948.
10. Mendis, K., A. Rietveld, M. Warsame, A. Bosman, B. Greenwood, and W. H. Wernsdorfer. 2009. From malaria control to eradication: the WHO perspective. Trop. Med. Int. Health 14:802-809.
11. Nathoo, S., L. Serghides, and K. C. Kain. 2003. Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes. Lancet 362:1039-1041.
12. Otieno, R. O., C. Ouma, J. M. Ong'echa, C. C. Keller, T. Were, E. N. Waindi, M. G. Michaels, R. D. Day, J. M. Vulule, and D. J. Perkins. 2006. Increased severe anemia in HIV-1-exposed and HIV-1-positive infants and children during acute malaria. AIDS 20:275-280.
13. Parikh, S., J. Gut, E. Istvan, D. E. Goldberg, D. V. Havlir, and P. J. Rosenthal. 2005. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 49:2983-2985.
14. Peatey, C. L., T. S. Skinner-Adams, M. W. Dixon, J. S. McCarthy, D. L. Gardiner, and K. R. Trenholme. 2009. Effect of antimalarial drugs on Plasmodium falciparum gametocytes. J. Infect. Dis. 200:1518-1521.
15. Redmond, A. M., T. Skinner-Adams, K. T. Andrews, D. L. Gardiner, J. Ray, M. Kelly, and J. S. McCarthy. 2007. Antimalarial activity of sera from subjects taking HIV protease inhibitors. AIDS 21:763-765.
16. Skinner-Adams, T. S., K. T. Andrews, L. Melville, J. McCarthy, and D. L. Gardiner. 2007. Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 51:759-762.
17. Skinner-Adams, T. S., J. S. McCarthy, D. L. Gardiner, and K. T. Andrews. 2008. HIV and malaria co-infection: interactions and consequences of chemotherapy. Trends Parasitol. 24:264-271.
18. Skinner-Adams, T. S., J. S. McCarthy, D. L. Gardiner, P. M. Hilton, and K. T. Andrews. 2004. Antiretrovirals as antimalarial agents. J. Infect. Dis. 190:1998-2000.
19. ter Kuile, F. O., M. E. Parise, F. H. Verhoeff, V. Udhayakumar, R. D. Newman, A. M. van Eijk, S. J. Rogerson, and R. W. Steketee. 2004. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. Am. J. Trop. Med. Hyg. 71:41-54.
20. Whitworth, J., D. Morgan, M. Quigley, A. Smith, B. Mayanja, H. Eotu, N. Omoding, M. Okongo, S. Malamba, and A. Ojwiya. 2000. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 356:1051-1056.